Genentech and Arvinas Inc. entered into a license agreement for the development of new therapeutics using Arvinas’ PROTAC technology. The multi-year strategic license agreement encompasses multiple disease targets.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
